Thrombophilias: A Comprehensive Review of Inherited and Acquired Hypercoagulable States

Abstract

Thrombophilia encompasses a spectrum of inherited and acquired disorders that predispose individuals to pathological thrombosis. This review examines the pathophysiology, clinical presentation, diagnostic approach, and management of the major thrombophilic conditions, including antithrombin deficiency, protein C and protein S deficiencies, factor V Leiden, prothrombin gene mutation 20210A, hyperhomocysteinemia, antiphospholipid antibody syndrome, and heparin-induced thrombocytopenia. Understanding these conditions is essential for appropriate risk stratification, prophylaxis, and treatment of thrombotic events.

1. Introduction

Thrombosis represents a complex interplay between vascular, hematological, and flow-related factors, classically described by Virchow's triad: endothelial injury, altered blood flow, and imbalance between procoagulant and anticoagulant factors. The vascular endothelium normally maintains an antithrombotic phenotype; however, under conditions of disrupted flow—such as at vascular bifurcations or stenoses—endothelial cells may become activated and prothrombotic. Thrombophilias, whether inherited or acquired, disturb the delicate equilibrium of hemostasis, leading to an increased propensity for venous and/or arterial thrombosis.

2. Assessment of Patients with Thrombotic Disorders

The clinical evaluation of a patient with thrombosis requires systematic consideration of several factors:

Age of onset: The mean age at first thrombosis in patients with inherited thrombophilia is 35–40 years. Early-onset thrombosis, particularly in the second decade of life, strongly suggests an underlying hereditary predisposition.

Presence of provoking factors: Common triggers include surgery, trauma, pregnancy, malignancy, prolonged immobilization, and infection. Idiopathic thrombosis in young individuals is highly suggestive of an underlying hypercoagulable state.

Family history: Objectively documented venous thromboembolism before age 50 in a first-degree relative strongly suggests hereditary thrombophilia. However, a negative family history does not exclude a genetic condition, as clinical thrombosis often results from the convergence of multiple risk factors.

Recurrence and site of thrombosis: Recurrent thrombosis increases the likelihood of an underlying hypercoagulable state. Thrombosis at atypical sites—such as hepatic, mesenteric, or cerebral veins—similarly raises suspicion for thrombophilia. Arterial thrombosis warrants a different diagnostic approach than venous thrombosis, with particular attention to antiphospholipid syndrome and hyperhomocysteinemia.

3. Hereditary Hypercoagulable States

3.1 Antithrombin Deficiency

Antithrombin (AT) inactivates factor Xa and thrombin by forming stable stoichiometric complexes, a process accelerated by heparin. Inherited AT deficiency occurs in approximately 1 in 2,000 individuals and follows an autosomal dominant pattern. Type I deficiency is quantitative, with reduced antigenic and functional levels (25–60% of normal), while Type II is qualitative, with normal antigen levels but dysfunctional protein.

Patients with AT deficiency exhibit increased incidence of venous thrombosis, typically triggered by prothrombotic stimuli. By age 50, only 10% of affected individuals remain thrombosis-free. Diagnosis requires functional assay, as antigenic assays alone miss Type II deficiency. Treatment of acute episodes requires heparin, though heparin resistance may occur due to the very mechanism of heparin action; in such cases, AT concentrates or fresh frozen plasma may be necessary. Long-term management involves warfarin, with lifelong therapy indicated after a thrombotic event.

3.2 Protein C and Protein S Deficiency

Protein C and its cofactor protein S inactivate factors VIIIa and Va, thereby regulating amplification of the coagulation cascade. Heterozygous protein C deficiency occurs in approximately 1 in 200–300 individuals, though phenotypic variability is considerable. Homozygous deficiency causes lethal thrombosis in neonates.

Protein S deficiency similarly predisposes to venous thrombosis, including mesenteric vein thrombosis. Pregnancy and oral contraceptives lower protein S levels, potentially unmasking deficiency. Functional assays are preferred for diagnosis, with free protein S measurement particularly important, as some patients have normal total but low free protein S.

A critical consideration in initiating warfarin therapy is the short half-life of protein C (6–7 hours), which creates a transient hypercoagulable window when warfarin is started. Heparin coadministration is essential during initiation to prevent warfarin-induced skin necrosis, a rare but devastating complication.

3.3 Factor V Leiden

Factor V Leiden (R506Q mutation) is the most common hereditary thrombophilia, present in approximately 5% of the white population. The mutation renders activated factor V resistant to cleavage by activated protein C (APC), resulting in prolonged factor Va activity and enhanced thrombin generation. Additionally, normal factor V serves as an APC cofactor in factor VIIIa inhibition; factor V Leiden impairs this function as well.

The relative risk of thrombosis in heterozygotes is 4–8-fold increased, rising to more than 30-fold when combined with oral contraceptive use. Homozygotes face an approximately 80-fold increased risk. Despite its high prevalence, factor V Leiden is a relatively weak risk factor, and first thrombotic events often occur later than with other thrombophilias. DNA-based testing allows precise diagnosis regardless of anticoagulation status.

Management parallels other hereditary deficiencies: 6 months of anticoagulation after first episode, with lifelong therapy for recurrent events. Carriers should avoid oral contraceptives, and pregnancy management remains individualized, with postpartum prophylaxis often considered.

3.4 Prothrombin Gene Mutation 20210A

A G-to-A transition at nucleotide 20210 in the 3' untranslated region of the prothrombin gene increases prothrombin levels and thrombotic risk. The prevalence is approximately 2.3% in healthy individuals, with higher frequencies in southern Europeans. The relative risk of thrombosis (2.8-fold) is similar to factor V Leiden. Combined heterozygosity for both mutations significantly increases recurrent thrombosis risk.

3.5 Hyperhomocysteinemia

Homocysteine metabolism involves remethylation to methionine (requiring folate, vitamin B12, and MTHFR) or transsulfuration to cysteine (requiring vitamin B6 and cystathionine β-synthase). Elevated homocysteine promotes endothelial dysfunction, inhibits thrombomodulin expression, and enhances lipoprotein(a) binding to fibrin.

Severe hyperhomocysteinemia (>100 μmol/L) from homozygous cystathionine β-synthase deficiency causes early-onset arterial and venous thrombosis along with mental retardation and ectopic lens. Mild-to-moderate elevations (16–100 μmol/L) are more common and associated with both arterial and venous disease. The thermolabile MTHFR variant (homozygous prevalence 5%) is clinically relevant only with inadequate folate intake.

Diagnosis requires fasting plasma homocysteine measurement; methionine loading tests identify an additional 40% of cases. Treatment with pyridoxine (250 mg) and folic acid (5 mg) daily normalizes levels in most patients, though whether this reduces thrombotic risk remains unproven.

3.6 Lipoprotein(a)

Lipoprotein(a) [Lp(a)] consists of LDL particles bound to apoprotein(a), which structurally resembles plasminogen and competitively inhibits plasminogen binding to endothelium, thereby impairing fibrinolysis. Elevated Lp(a) is an independent risk factor for coronary artery disease, with levels >25–30 mg/dL considered significant. Management focuses on standard cardiovascular risk reduction; niacin and tamoxifen may lower Lp(a) levels.

3.7 Dysfibrinogenemia and Abnormal Fibrinolysis

Approximately 300 abnormal fibrinogens have been described, with about half clinically silent. Thrombosis and bleeding occur with roughly equal frequency in symptomatic cases. Diagnosis reveals discrepant antigenic and functional fibrinogen levels with prolonged thrombin and reptilase times. Abnormal plasminogens and elevated plasminogen activator inhibitor-1 have been associated with thrombosis, though their clinical significance requires further study.

3.8 Elevated Coagulation Factors

Elevated factor VIII (>90th percentile) confers approximately 5-fold increased risk of first DVT and increased recurrence risk. Elevated fibrinogen and factor VII are independent risk factors for coronary artery disease.

4. Acquired Hypercoagulable States

4.1 Antiphospholipid Antibody Syndrome

Antiphospholipid antibody syndrome (APS) is characterized by autoantibodies against phospholipid-binding proteins, most commonly β2-glycoprotein I and prothrombin. The syndrome may be primary or secondary to systemic lupus erythematosus, infections, malignancies, or drugs.

Thrombotic events occur in approximately 30% of affected patients, with venous and arterial thrombosis both observed. The recurrence rate is alarmingly high (50–70% without prolonged anticoagulation). Diagnosis requires clinical criteria (thrombosis or pregnancy morbidity) plus laboratory confirmation: lupus anticoagulant by phospholipid-dependent clotting assays or anticardiolipin antibodies (IgG >20 GPL or IgM >20 MPL) by ELISA. Testing must be positive on two occasions at least 6 weeks apart.

Acute treatment of DVT uses low-molecular-weight heparin (LMWH), circumventing the problem of lupus anticoagulant prolonging aPTT. Long-term warfarin to INR 2.0–3.0 is effective for most patients, though some with recurrent thrombosis on conventional therapy require higher intensity. For pregnancy, heparin plus low-dose aspirin (81 mg) achieves 70–80% viable delivery rates, superior to aspirin alone.

4.2 Heparin-Induced Thrombocytopenia

Heparin-induced thrombocytopenia (HIT) occurs in approximately 1% of patients receiving porcine unfractionated heparin and 5% receiving bovine heparin, with lower incidence with LMWH. Pathophysiology involves IgG antibodies against the platelet factor 4 (PF4)-heparin complex, leading to platelet activation via FcγRII receptors, thrombocytopenia, and paradoxical thrombosis.

HIT typically develops 5–10 days after heparin initiation, though rapid onset may occur with prior sensitization. Thrombocytopenia (platelet count <150 × 10⁹/L or >50% drop from peak) is accompanied by thrombosis in 30–50% of cases. Diagnosis relies primarily on clinical findings; PF4-heparin ELISA offers high sensitivity but imperfect specificity.

Management requires immediate cessation of all heparin and initiation of alternative anticoagulation: lepirudin (recombinant hirudin, renally cleared), argatroban (hepatically cleared), or fondaparinux (synthetic pentasaccharide, does not bind PF4). Warfarin must not be started until platelet counts normalize and should overlap with alternative agents for at least 5 days to prevent limb gangrene.

4.3 Trousseau Syndrome

Trousseau syndrome describes cancer-associated thrombosis, particularly with mucin-secreting adenocarcinomas (pancreas, ovary, lung, colon, breast). The underlying mechanism involves chronic, compensated disseminated intravascular coagulation with tumor expression of tissue factor and cancer procoagulant. Patients present with migratory superficial thrombophlebitis or DVT, often with concurrent arterial thromboembolism from nonbacterial thrombotic endocarditis.

Coagulation studies show subtle DIC evidence with elevated D-dimer. Cancer patients have increased recurrent thrombosis and bleeding during warfarin therapy, attributed to relative warfarin resistance and tumor-related bleeding. LMWH (dalteparin) reduces recurrent thrombosis by 50% compared to oral anticoagulation, making it the preferred long-term therapy.

4.4 Estrogen-Related Thrombosis

Oral contraceptives increase thromboembolic risk approximately 4-fold, with third-generation progestins (desogestrel) carrying twice the risk of second-generation agents (levonorgestrel). The absolute risk remains low, but the combination with factor V Leiden creates a 50-fold increased risk. Postmenopausal hormone replacement increases risk 3-fold (absolute risk ~3.2 per 10,000 patient-years). Patients with prior thrombosis should avoid estrogen therapy.

5. Management of Venous Thromboembolism

The intensity and duration of anticoagulation must be individualized based on recurrence risk:

High risk (lifelong anticoagulation, INR 2.0–3.0): Recurrent idiopathic thrombosis, life-threatening thrombosis, spontaneous thrombosis at unusual sites, antiphospholipid antibody syndrome, thrombosis with multiple permanent risk factors, Trousseau syndrome.

Medium risk (6 months anticoagulation): Thrombosis with one permanent risk factor, idiopathic thrombosis without identifiable risk factors.

Low risk (6 weeks–3 months): Thrombosis with reversible risk factors.

An INR of 2.0–3.0 provides optimal balance between efficacy and bleeding risk. Even 12 months of warfarin after idiopathic DVT does not reduce post-treatment recurrence, with approximately 10% recurrence in the first 6–12 months after discontinuation. Persistently elevated D-dimer one month after warfarin cessation identifies higher-risk patients who may benefit from extended therapy.

6. Conclusion

Thrombophilias represent a diverse group of inherited and acquired conditions that significantly impact thrombotic risk. Rational clinical assessment—considering age, triggers, family history, recurrence, and thrombosis site—guides the extent and timing of hypercoagulable workup. While factor V Leiden and prothrombin mutation are common, they confer modest risk; antithrombin deficiency and antiphospholipid syndrome carry substantially higher thrombotic potential. Management strategies must balance the benefits of anticoagulation against bleeding risks, with particular attention to pregnancy, surgery, and cancer-associated thrombosis. Ongoing research will further refine risk stratification and therapeutic approaches for these challenging conditions.